

CITATION REPORT

List of articles citing

Sympathetic activation by sildenafil

DOI: 10.1161/01.cir.102.25.3068
Circulation, 2000, 102, 3068-73.

Source: <https://exaly.com/paper-pdf/31748619/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
111	Sildenafil Does Not Influence Autonomic Neurocardiac Control Assessed by Standard Measurements of Heart Rate Variability. <i>Circulation</i> , 2001 , 104,	16.7	1
110	Sympathetic Activation by Sildenafil. <i>Circulation</i> , 2001 , 104,	16.7	
109	Transient ischemic attack and stroke associated with sildenafil (Viagra) use. 2001 , 57, 1730-1		58
108	Current World Literature. 2001 , 10, 699-725		
107	The effect of sildenafil on nitric oxide-mediated vasodilation in healthy men. 2001 , 70, 270-9		49
106	Effect of sildenafil on blood pressure and arterial wave reflection in treated hypertensive men. 2001 , 15, 707-13		77
105	Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. <i>Circulation</i> , 2001 , 104, 1218-22	16.7	345
104	[Interaction between sildenafil and antihypertensive drugs: what is evidence-based?]. 2001 , 126, 1144-9		7
103	Interaction of sildenafil with cAMP-mediated vasodilation in vivo. 2002 , 40, 763-7		24
102	Effects of selective angiotensin II receptor blockade on sympathetic nerve activity in primary hypertensive subjects. 2002 , 20, 1143-9		60
101	Sildenafil (Viagra) augments sodium nitroprusside-induced but not nitroglycerin-induced hypotension in dogs. 2002 , 94, 1505-9, table of contents		1
100	Sildenafil (Viagra) Augments Sodium Nitroprusside-Induced But Not Nitroglycerin-Induced Hypotension in Dogs. 2002 , 94, 1505-1509		9
99	Effect of sildenafil on renin secretion in human subjects. 2002 , 227, 620-5		13
98	Current World Literature. 2002 , 11, 237-266		
97	Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. <i>Circulation</i> , 2002 , 105, 2398-403	16.7	508
96	The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. 2002 , 40, 1232-40		238
95	Effects of sildenafil citrate (viagra) on cardiac repolarization and on autonomic control in subjects with chronic heart failure. 2002 , 143, 703-10		45

94	Coronary and systemic hemodynamic effects of sildenafil citrate: from basic science to clinical studies in patients with cardiovascular disease. 2002 , 86, 131-41		64
93	Neurologic, psychological, and aggressive disturbances with sildenafil. 2002 , 36, 1129-34		76
92	[Cardio-vascular effects of sildenafil: new data]. 2002 , 51, 341-5		3
91	Sildenafil, a phosphodiesterase-5 inhibitor, delays gastric emptying and gastrointestinal transit of liquid in awake rats. 2003 , 48, 2064-8		23
90	The role of the NO axis and its therapeutic implications in pulmonary arterial hypertension. 2003 , 8, 5-21		51
89	Coronary artery flow reserve in diabetics with erectile dysfunction using sildenafil. 2003 , 2, 8		5
88	Sildenafil response is influenced by the G protein beta 3 subunit GNB3 C825T polymorphism: a pilot study. 2003 , 169, 1048-51		35
87	Effects of sildenafil on cardiopulmonary responses during stress. 2003 , 169, 1417-21		6
86	Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease. <i>Circulation</i> , 2003 , 108, 239-44	16.7	124
85	Sildenafil in erectile dysfunction: a critical review. 2003 , 19, 241-62		77
84	Genetic risk factors for erectile dysfunction and genetic determinants of drug response--on the way to improve drug safety?. 2003 , 28, 304-13		14
83	[Sildenafil does not change coronary flow reserve in diabetics with erectile dysfunction]. 2003 , 128, 190-5		5
82	Use of sildenafil for safe improvement of erectile function and quality of life in men with New York Heart Association classes II and III congestive heart failure: a prospective, placebo-controlled, double-blind crossover trial. 2004 , 164, 514-20		65
81	Long-term treatment with a phosphodiesterase type 5 inhibitor improves pulmonary hypertension secondary to heart failure through enhancing the natriuretic peptides-cGMP pathway. 2004 , 44, 596-600		13
80	The Role of the NO Axis and its Therapeutic Implications in Pulmonary Arterial Hypertension. 2004 , 213-229		
79	Sildenafil citrate does not alter ventricular repolarization properties: novel evidence from dynamic QT analysis. 2004 , 9, 228-33		5
78	Haemodynamic effects of the selective phosphodiesterase 5 inhibitor, UK-357,903, in conscious SHR. 2004 , 141, 114-22		5
77	Sildenafil. 2004 ,		

76	Sildenafil: emerging cardiovascular indications. 2004 , 78, 1496-506	53
75	Autonomic control of the cardiovascular system during acclimatization to high altitude: effects of sildenafil. 2004 , 97, 935-40	57
74	Erectile dysfunction drugs and non-arteritic anterior ischemic optic neuropathy: is there a cause and effect relationship?. 2005 , 25, 295-8	47
73	Inhibition of angiotensin-converting enzyme and phosphodiesterase type 5 improves endothelial function in heart failure. 2005 , 108, 331-8	39
72	Phosphodiesterase 5 inhibition in chronic heart failure and pulmonary hypertension. 2005 , 96, 47M-51M	150
71	Effect of sildenafil on reperfusion function, infarct size, and cyclic nucleotide levels in the isolated rat heart model. 2005 , 19, 23-31	40
70	Inhibition of cGMP-specific phosphodiesterase type 5 reduces sodium excretion and arterial blood pressure in patients with NaCl retention and ascites. 2005 , 288, F1044-52	22
69	Sildenafil inhibits beta-adrenergic-stimulated cardiac contractility in humans. <i>Circulation</i> , 2005 , 112, 2642-7	142
68	Hemodynamic effects of phosphodiesterase 5 and angiotensin-converting enzyme inhibition alone or in combination in conscious SHR. 2005 , 312, 265-71	5
67	Aggressive behavior increases after termination of chronic sildenafil treatment in mice. 2005 , 83, 683-8	29
66	Pharmacotherapy of erectile dysfunction: focus on cardiovascular safety. 2005 , 4, 531-40	18
65	Treatment of pulmonary arterial hypertension with sildenafil: from pathophysiology to clinical evidence. 2006 , 20, 722-35	22
64	Effects of sildenafil on hypoxic pulmonary vascular function in dogs. 2006 , 101, 1085-90	28
63	Sildenafil reduces cardiovascular remodeling associated with hypertensive cardiomyopathy in NOS inhibitor-treated rats. 2006 , 542, 141-7	30
62	Effect of intravenous sildenafil on pulmonary hemodynamics and gas exchange in the presence and absence of acute lung injury in piglets. 2006 , 59, 762-6	13
61	Cardioprotection with sildenafil: implications for clinical practice. 2006 , 13, 3155-64	16
60	Cardiovascular effects of phosphodiesterase 5 inhibitors. 2006 , 12, 3485-94	45
59	The effects of intravenous sildenafil on hemodynamics and cardiac sympathetic activity in chronic human heart failure. 2006 , 8, 864-8	23

58	The effects of sildenafil on heart rate variability in healthy subjects. 2007 , 50, 598-600	4
57	Chronic treatment with sildenafil improves energy balance and insulin action in high fat-fed conscious mice. 2007 , 56, 1025-33	186
56	Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease. 2007 , 15, 76-86	52
55	Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. <i>Circulation</i> , 2007 , 116, 238-48	16.7 420
54	Effect of sildenafil and rolipram on adrenergic responses in isolated human and monkey corpus cavernosum. 2007 , 52, 253-8	6
53	Sildenafil and phosphodiesterase-5 inhibitors for heart failure. 2008 , 5, 110-4	17
52	ADR Frequency and Signal Informations Related with Sildenafil in South Korea. 2008 , 31, 885-960	0
51	Clinical use of phosphodiesterase-5 inhibitors in chronic heart failure. 2008 , 1, 272-80	43
50	Does sildenafil cause myocardial infarction or sudden cardiac death?. 2008 , 8, 1-7	18
49	Non-arteritic anterior ischaemic optic neuropathy and phosphodiesterase-5 inhibitors. 2008 , 92, 1577-80	28
48	Sildenafil acts on the central nervous system increasing sympathetic activity. 2008 , 104, 1683-9	25
47	Nonarteritic anterior ischaemic optic neuropathy. 2008 , 19, 461-7	12
46	An open-label pilot study to evaluate the efficacy of sildenafil citrate in middle-aged men with late-onset dysthymia. 2008 , 196, 496-500	4
45	Tadalafil improves oxygenation in a model of newborn pulmonary hypertension. 2008 , 9, 330-2	20
44	PDE5 inhibitors in non-urological conditions. 2009 , 15, 3521-39	24
43	Phosphodiesterase 5 inhibition in heart failure: mechanisms and clinical implications. 2009 , 6, 349-55	25
42	Acute effects of sildenafil on flow mediated dilatation and cardiovascular autonomic nerve function in type 2 diabetic patients. 2009 , 25, 136-43	17
41	Pivotal effects of phosphodiesterase inhibitors on myocyte contractility and viability in normal and ischemic hearts. 2009 , 30, 1-24	45

40	Transpulmonary B-type natriuretic peptide uptake and cyclic guanosine monophosphate release in heart failure and pulmonary hypertension: the effects of sildenafil. 2009 , 54, 595-600	54
39	Sildenafil increases the force of right atrial contractions in vitro via the NO-guanylyl cyclase pathway involving β adrenoceptor linked mechanisms. 2009 , 61, 1146-52	3
38	Phosphodiesterase 5 inhibitors: are they cardioprotective?. 2009 , 83, 204-12	29
37	Effects of sildenafil treatment on the development of tolerance to diazepam-induced motor impairment and sedation in mice. 2010 , 62, 627-34	16
36	Sildenafil counteracts the inhibitory effect of social subordination on competitive aggression and sexual motivation in male mice. 2011 , 216, 193-9	9
35	Effects of phosphodiesterase type 5 inhibitors on endothelial function and cardiovascular autonomic nerve function in men. 2011 , 8, 109-118	2
34	Subarachnoid hemorrhage during sexual activity after sildenafil intake: an accidental association?. 2011 , 32, 310-1	7
33	Application of cardiac autonomous indices in the study of neurogenic erectile dysfunction. 2011 , 86, 290-7	
32	The phosphodiesterases type 5 inhibitor tadalafil reduces the activation of the hypothalamus-pituitary-adrenal axis in men during cycle ergometric exercise. 2012 , 302, E972-8	14
31	Partial motor restoration upon administration of sildenafil: a case study. 2012 , 15, 39-43	5
30	Endothelial dysfunction enhances the pulmonary and systemic vasodilator effects of phosphodiesterase-5 inhibition in awake swine at rest and during treadmill exercise. 2012 , 237, 201-10	9
29	Effect of sildenafil on ventricular arrhythmias in post-infarcted rat hearts. 2012 , 690, 124-32	8
28	Inhibition of sympathetic neuroeffector transmission in human corpus cavernosum. 2012 , 110, 856-62	8
27	Effects of epoprostenol and sildenafil on right ventricular function in hypoxic volunteers: a tissue Doppler imaging study. 2012 , 112, 1285-94	15
26	Experimental evidence for sildenafil's action in the central nervous system: dopamine and serotonin changes in the medial preoptic area and nucleus accumbens during sexual arousal. 2013 , 10, 719-29	25
25	Sildenafil increases sympathetically mediated vascular tone in humans. 2013 , 26, 762-9	12
24	Sympathoneural and adrenomedullary responses to mental stress. 2015 , 5, 119-46	43
23	Polymorphism of the G protein β subunit gene influences the efficacy of sildenafil in patients with pulmonary hypertension. 2014 , 53, 291-7	9

22	Impaired neuronal nitric oxide synthase-mediated vasodilator responses to mental stress in essential hypertension. 2015 , 65, 903-9		13
21	Endothelial dysfunction markers as a therapeutic target for Sildenafil treatment and effects on metabolic control in type 2 diabetes. 2015 , 19, 1617-22		30
20	Role of Phosphodiesterase 5 and Cyclic GMP in Hypertension. 2016 , 18, 39		24
19	Are Erectile Dysfunction Medications Causally Related to Nonarteritic Anterior Ischemic Optic Neuropathy?. 2016 , 36, 202-7		4
18	Use of β Blockers in Pulmonary Hypertension. 2017 , 10,		41
17	Potential of the NO-cGMP pathway and blood flow responses during dynamic exercise in healthy humans. 2017 , 117, 237-246		4
16	Neuroprotective effects of sildenafil against oxidative stress and memory dysfunction in mice exposed to noise stress. 2017 , 319, 37-47		16
15	Sildenafil induces browning of subcutaneous white adipose tissue in overweight adults. 2018 , 78, 106-117		29
14	Exercise Training Plus Sildenafil Treatment: Role on Autonomic and Inflammatory Markers. 2018 , 39, 749-756		
13	Sildenafil does not reliably improve exercise performance in hypoxia: a systematic review. 2019 , 5, e000526		2
12	Combined Intravenous Sildenafil and L-Arginine Administration in a Porcine Animal Model: Hemodynamic Safety Profile and Effects on Coronary Blood Flow. 2020 , 20, 279-290		
11	Sildenafil in ophthalmology: An update. <i>Survey of Ophthalmology</i> , 2021 ,	6.1	3
10	The NO - K ⁺ channel axis in pulmonary arterial hypertension. Activation by experimental oral therapies. <i>Advances in Experimental Medicine and Biology</i> , 2003 , 543, 293-322	3.6	16
9	Pathogenesis of Some Controversial Non-arteritic Anterior Ischemic Optic Neuropathy Clinical Entities. 2011 , 317-336		1
8	Sildenafil pre-treatment promotes decompression sickness in rats. <i>PLoS ONE</i> , 2013 , 8, e60639	3.7	16
7	Role of cGMP and cAMP in the hemodynamic response to intrathecal sildenafil administration. <i>Clinics</i> , 2011 , 66, 1407-12	2.3	3
6	Etiologies and Mechanisms of Ischemic Stroke Associated with Sexual Intercourse: A Literature Review. <i>Cerebrovascular Diseases</i> , 2021 , 1-9	3.2	
5	Cardiovascular Safety of Sexual Activity and Phosphodiesterase Type 5 Inhibition. 2004 , 159-181		

4 Erectile Dysfunction and Cardiovascular Disease. **2007**, 2791-2801

3 Cardiac Issues Related to Erectile Dysfunction. **2006**, 61-75

2 Clinical outcomes of sildenafil application in patients of poor endometrial development.
Gynecology and Obstetrics Clinical Medicine, **2022**, 2, 14-19

1 Sildenafil affects the human Kir2.1 and Kir2.2 channels at clinically relevant concentrations:
Inhibition potentiated by low Ba²⁺. 14,

1